NorthX Biologics completed the acquisition of a biologics manufacturing unit from Valneva.

NorthX Biologics, a Nordic development and manufacturing organisation, completed the acquisition of a biologics manufacturing unit from Valneva, a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines. Financial terms were not disclosed. “I am very proud when looking back at what we have achieved within the unit over the past years and look forward with great enthusiasm to build on NorthX’s position as the go-to manufacturer of advanced biologics in Northern Europe," Janet Hoogstraate, Valneva Sweden Managing Director.